This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (5)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

To the Editor: Dr Bridges and colleagues¹ found that provision of influenza vaccination to healthy working adults did not provide significant economic benefits. However, their findings should be applied to other settings with caution.

The trial was adequately sized and carefully executed. During year 1, however, there was a poor vaccine–circulating virus strain match. Vaccine efficacy was 50% (P = .33) against laboratory-confirmed influenza illness, but vaccine recipients otherwise tended to fare worse than placebo recipients. It is difficult to interpret these findings, given the impressive safety record of this vaccine and numerous studies demonstrating its clinical effectiveness. In year 2 there was a good vaccine–circulating virus match. Vaccine efficacy was 86%, and vaccination reduced clinical outcomes. However, net vaccination costs were $11.17 per person.

Two key parameters for the economic analysis in year 2 were rates of illness and time lost from work. The illness rate among unvaccinated . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Economic Analysis of Influenza Vaccination and Antiviral Treatment for Healthy Working Adults
Lee et al.
ANN INTERN MED 2002;137:225-231.
ABSTRACT | FULL TEXT